301. Current advances in γδ T cell-based tumor immunotherapy
- Author
-
Elena Lo Presti, Gabriele Pizzolato, Eliana Gulotta, Gianfranco Cocorullo, Gaspare Gulotta, Francesco Dieli, Serena Meraviglia, Presti, E., Pizzolato, G., Gulotta, E., Cocorullo, G., Gulotta, G., Dieli, F., and Meraviglia, S.
- Subjects
0301 basic medicine ,lcsh:Immunologic diseases. Allergy ,Adoptive cell transfer ,adoptive transfer ,T cell ,Immunology ,Review ,Biology ,Major histocompatibility complex ,γδ T cells ,03 medical and health sciences ,Interleukin 21 ,0302 clinical medicine ,Adoptive transfer ,Immunoevasion ,Immunotherapy ,Zoledronate ,γδ T cells ,Immunology and Allergy ,MHC class I ,medicine ,Cytotoxic T cell ,Adoptive transfer Immunoevasion Immunotherapy Zoledronate γδ T cells ,Gamma delta T cell ,γδ T cell ,MHC restriction ,030104 developmental biology ,medicine.anatomical_structure ,biology.protein ,immunoevasion ,immunotherapy ,lcsh:RC581-607 ,030215 immunology - Abstract
γδ T cells are a minor population (~5%) of CD3 T cells in the peripheral blood, but abound in other anatomic sites such as the intestine or the skin. There are two major subsets of γδ T cells: those that express Vd1 gene, paired with different Vγ elements, abound in the intestine and the skin, and recognize the major histocompatibility complex (MHC) class I-related molecules such as MHC class I-related molecule A, MHC class I-related molecule B, and UL16-binding protein expressed on many stressed and tumor cells. Conversely, γδ T cells expressing the Vδ2 gene paired with the Vγ9 chain are the predominant (50-90%) γδ T cell population in the peripheral blood and recognize phosphoantigens (PAgs) derived from the mevalonate pathway of mammalian cells, which is highly active upon infection or tumor transformation. Aminobisphosphonates (n-BPs), which inhibit farnesyl pyrophosphate synthase, a downstream enzyme of the mevalonate pathway, cause accumulation of upstream PAgs and therefore promote γδ T cell activation. γδ T cells have distinctive features that justify their utilization in antitumor immunotherapy: they do not require MHC restriction and are less dependent that aà T cells on co-stimulatory signals, produce cytokines with known antitumor effects as interferon-? and tumor necrosis factor-a and display cytotoxic and antitumor activities in vitro and in mouse models in vivo. Thus, there is interest in the potential application of γδ T cells in tumor immunotherapy, and several small-sized clinical trials have been conducted of γδ T cell-based immunotherapy in different types of cancer after the application of PAgs or n-BPs plus interleukin-2 in vivo or after adoptive transfer of ex vivo-expanded γδ T cells, particularly the Vγ9Vδ2 subset. Results from clinical trials testing the efficacy of any of these two strategies have shown that γδ T cell-based therapy is safe, but long-term clinical results to date are inconsistent. In this review, we will discuss the major achievements and pitfalls of the γδ T cell-based immunotherapy of cancer.
- Published
- 2017